Ultra Market Research | Canada EGFR and HER2 Targeted NSCLC Market
Canada EGFR and HER2 Targeted NSCLC Market
Report ID : 865
Category : Canada,Healthcare-Companies
No Of Pages : 144
Published on: November 2024
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
Introduction
The Canada EGFR & HER2 targeted NSCLC market is witnessing substantial growth due to advancements in precision medicine and targeted therapies. EGFR (Epidermal Growth Factor Receptor) and HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors are pivotal in treating non-small cell lung cancer (NSCLC), a prevalent cancer type. These therapies block specific proteins responsible for cancer cell proliferation, offering higher efficacy with fewer side effects compared to traditional chemotherapy. Canada's strong emphasis on oncology research and healthcare infrastructure has facilitated the adoption of these cutting-edge treatments. Recent trends highlight the growing use of combination therapies and biomarker-driven drug development, driving personalized care for NSCLC patients. With regulatory support and the introduction of novel therapies, the market is set to expand further.
Segmentation
Therapeutic Agents Targeted EGFR Inhibitors
First-generation EGFR inhibitors
Second-generation EGFR inhibitors
Third-generation EGFR inhibitors
Others
Targeted HER2 Inhibitors
Tyrosine kinase inhibitors (TKIs)
Monoclonal antibodies
Others
Combination Therapies
EGFR and HER2 inhibitors with immunotherapy
EGFR and HER2 inhibitors with chemotherapy
Others
Biomarker Testing and Diagnostics Testing Kits
EGFR mutation detection kits
HER2 amplification tests
Others
Service Providers
Hospital-based diagnostic services
Independent diagnostic labs
Others
List of Market Players
AstraZeneca (UK)
Roche Holding AG (Switzerland)
Pfizer Inc. (USA)
Eli Lilly and Company (USA)
Novartis AG (Switzerland)
Merck & Co., Inc. (USA)
Amgen Inc. (USA)
Boehringer Ingelheim (Germany)
Takeda Pharmaceutical Company Limited (Japan)
Daiichi Sankyo (Japan)
Johnson & Johnson (USA)
Bristol-Myers Squibb Company (USA)
AbbVie Inc. (USA)
Blueprint Medicines Corporation (USA)
Sanofi (France)
Drivers
The Canada EGFR & HER2 targeted NSCLC market is driven by the increasing prevalence of NSCLC and advancements in molecular diagnostics. A rise in awareness about biomarker-based therapies has enabled early detection, improving patient outcomes. Government initiatives and funding for cancer research further bolster market growth. The expanding portfolio of approved therapies, such as osimertinib for EGFR mutations and trastuzumab for HER2 amplifications, offers enhanced treatment options. Additionally, Canada's robust healthcare infrastructure facilitates access to innovative therapies, promoting the adoption of precision medicine. Collaborative efforts between pharmaceutical companies and research institutions are accelerating clinical trials and the development of next-generation drugs.
Restraints
Despite significant advancements, the Canada EGFR & HER2 targeted NSCLC market faces challenges such as high treatment costs and limited access in remote areas. Targeted therapies often require specialized diagnostic tests, which can be expensive and not widely available. Resistance to EGFR and HER2 inhibitors is another major hurdle, necessitating the development of alternative treatments. Regulatory complexities and lengthy approval processes can delay the launch of innovative therapies. Additionally, competition from biosimilars and generics impacts the profitability of branded therapies. The need for personalized treatment plans based on genetic profiling also limits scalability, posing challenges for healthcare providers and patients.
Opportunities
The rising adoption of liquid biopsies and next-generation sequencing technologies offers significant opportunities in the Canada EGFR & HER2 targeted NSCLC market. These advancements enable the identification of actionable mutations, driving personalized treatment. Increasing investment in oncology research by government and private entities fosters innovation in targeted therapies. Expanding clinical trials for novel combinations of EGFR and HER2 inhibitors with immune checkpoint inhibitors hold promise for improved efficacy. Partnerships between pharmaceutical companies and healthcare providers are likely to enhance access to advanced therapies in underserved regions. The growing emphasis on value-based care models presents opportunities for affordable, patient-centric solutions.
Trends
The market is experiencing a surge in research focused on overcoming resistance to EGFR and HER2 inhibitors. Novel therapies, such as bispecific antibodies and antibody-drug conjugates (ADCs), are gaining traction. The integration of artificial intelligence (AI) in biomarker discovery and drug development is streamlining research processes. Precision oncology programs are increasingly incorporating real-world data to optimize treatment strategies. Another notable trend is the rise of combination regimens involving targeted therapies and emerging modalities like CAR-T cells. Regulatory approvals of new therapies tailored for specific genetic subtypes further highlight the market's focus on personalized care.
EGFR & HER2 targeted therapies inhibit specific proteins involved in NSCLC progression, offering improved outcomes with fewer side effects compared to traditional treatments.
Canada's advanced healthcare infrastructure, focus on oncology research, and high prevalence of NSCLC make it a crucial market for EGFR & HER2 targeted therapies.
While access in remote areas remains a challenge, government initiatives and telemedicine solutions are improving availability.
Biomarkers identify specific genetic mutations, enabling personalized and effective treatment with targeted therapies.
Recent advancements include the development of bispecific antibodies, ADCs, and AI-driven drug discovery.
Executive Summary 1.1 Key Market Highlights 1.2 Market Size and Growth Overview 1.3 Key Trends in the Canada EGFR & HER2 Targeted NSCLC Market
Introduction 2.1 Definition and Scope 2.2 Application of EGFR & HER2 Targeted Therapies in NSCLC 2.3 Recent Market Trends
Drivers of the Canada EGFR & HER2 Targeted NSCLC Market
Factors Boosting Market Growth
Restraints of the Canada EGFR & HER2 Targeted NSCLC Market
Challenges in Market Growth
Opportunities in the Canada EGFR & HER2 Targeted NSCLC Market
Emerging Areas and Innovations
Approved EGFR & HER2 Targeted Therapies
Product Name and Approval Date
Pipeline, Registered, and Pre-Registered Products
Development Stage and Target Mutation
Target Audience for Market Research
List of Key Stakeholders
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings Internal and external proprietary databases, relevant patent and regulatory databases National government documents, statistical databases and market reports News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process Middle Circle Represents – Source of Information Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc. Helps in validating and strengthening the secondary research findings Further develops the analysis team’s expertise and market understanding Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers Purchasing managers, technical personnel, distributors and resellers Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment Macro-economic indicators: GDP, etc. Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities. Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps:
2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach. 2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of Canada EGFR & HER2 Targeted NSCLC Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region.
This report provides market size of Canada EGFR & HER2 Targeted NSCLC Market for the past year and forecasts for the next six years. Canada EGFR & HER2 Targeted NSCLC Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different Canada EGFR & HER2 Targeted NSCLC Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for Global Skincare Treatment from different application industries in different regions.
